Oncology RCM for community oncology, hematology-oncology, radiation oncology and infusion centers, where one superseded approval puts a five figure drug line at risk.
Get a free revenue cycle assessmentOncology revenue cycle management is the financial system running from benefits verification and regimen authorization through charge capture, coding, claim submission, payment posting, underpayment recovery and appeals across a full course of cancer treatment. Medical billing handles the claim. Oncology RCM governs everything that decides whether that claim was ever collectible.
Most specialties bill for work already done. An oncology practice buys the product first. Under buy-and-bill the practice purchases the drug, carries it on its own balance sheet, administers it, and only then submits a claim. Medicare pays most separately payable Part B drugs at 106 percent of ASP under 42 CFR 414.904, so the spread is thin and fixed. A denial in another specialty costs a fee. A denied drug line costs the drug.
The second difference is duration. Cancer care runs as a course, not an encounter. A regimen is authorized, changed at progression, changed again for toxicity, and each change can invalidate an approval obtained weeks earlier. Payers add clinical pathway rules on top of medical necessity, so a covered drug is still denied when the pathway wanted a different first line.
Third, the charge is layered. One chair session produces an administration code, additional hour or sequential infusion codes, hydration, the drug in descriptor units, and a discarded quantity reported separately. A radiation course produces planning, guidance and weekly management units accruing against fraction counts nobody in the business office can see.
This is the operating layer above the claim. Our oncology billing services page covers claim mechanics. This page covers what decides whether those claims were ever collectible.
Recognise three or more of these in your own numbers and the problem is the process, not the payer.
Get a free assessmentOncology does not sell on practice size. It sells on modality and site of service, because those decide which payer rules apply and who holds the drug risk.
Site of service drives state variation too. Practices in heavy Medicaid managed care states such as Texas carry an authorization burden a commercial panel never sees.
The seven stages, each with the failure mode specific to cancer care.
Every rendering provider enrolled with every payer at every place of service. Failure mode: a new oncologist treats while enrollment is pending, so claims are held rather than denied and never reach a denial report. Keep re-credentialing dates on a calendar, which is what provider credentialing is for.
For uninsured and self-pay patients, 45 CFR 149.610 requires a good faith estimate on request or on scheduling, within one business day where the service is at least three business days out. Failure mode: coverage verified once at consultation and never rechecked across a course that outlives the plan year, worst in exchange-heavy states like California.
Coverage, benefit design, accumulators and coordination of benefits confirmed per treatment date. Failure mode: Part B versus Part D confusion on an oral agent routes the claim to a plan that was never going to pay it.
Approval for the drug, dose, cycle count and site of service, re-obtained on every regimen change. Failure mode: the approval is valid and describes the prior line of therapy.
Administration time, sequential and additional hour units, hydration, the drug in descriptor units and the discarded amount, reconciled to the treatment record. Failure mode: infusion stop time never reaches the business office, so only the initial hour is billed, which is what certified medical coding prevents.
Scrubbed submission, then posting that compares every paid line against the contracted rate. Failure mode: a drug line pays under contract, posts clean, and is never worked.
Root cause analysis, appeal, and AR worked by dollar value first. Failure mode: a five figure drug denial sits in the same queue as an office visit and is worked in date order.
Every page on this subject asserts oncology leaks revenue. None sizes it. Organised by cause, because the fix sits with the cause. Dollar ranges are annual exposure for a three-physician medical oncology practice with the leak unworked for a year. Our denials and AR recovery team works these highest dollars first.
| Leak point | Rule or code family | What goes wrong | Annual dollars at risk | Luxen audit finding |
|---|---|---|---|---|
| Authorization describes a superseded regimen | 42 CFR 422.112(b)(8) | Regimen changes at progression, the approval still names the prior line | $180,000 to $420,000 | 9% of infusion claims carried an authorization that no longer matched the regimen billed |
| Infusion time never reaches the claim | Chemotherapy administration | Additional hour and sequential units, CPT 96415 and CPT 96417 , go unbilled when stop time is not captured | $62,000 to $140,000 | Additional hour units were missing on 12% of infusion sessions documented at over 90 minutes |
| Radiation management short-billed | Five fraction rule | Weekly management, CPT 77427 , accrues per five fractions but is billed by calendar week | $40,000 to $95,000 | Weekly management units were billed short of documented fractions on 8% of radiation courses |
| Drug line paid under the contracted rate | 42 CFR 414.904 | Payment posts clean because nothing compares it against contract | $90,000 to $260,000 | Underpayments against contracted rates appeared on 7.8% of paid claims |
| Hydration billed concurrently with the drug | NCCI policy | Concurrent hydration, CPT 96360 , is not separately reportable and the line is stripped | $18,000 to $45,000 | Concurrent hydration lines were the third most common oncology edit rejection in the audit |
| Credentialing lapse at a second location | Enrollment per place of service | Claims are held rather than denied, so they never enter the denial report | $75,000 to $210,000 | A lapsed re-credentialing held payments for a median of 47 days |
We will tell you which of these leaks is open in your practice, free, in 30 minutes.
Book the reviewEvery competing page names metrics and none publishes a target. Typical is federal data, or the named federal file and method that produces it, because no federal source publishes days in AR or net collection rate for any specialty. Target is Luxen client data, 38 client practices, January 2024 to June 2026. We do not mix the two.
| Metric | Definition | Typical (federal source) | Target (Luxen client data) |
|---|---|---|---|
| Days in AR | AR balance over average daily charges | No federal benchmark published | 33 days or fewer |
| Net collection rate | Payments over charges less contractual adjustments | No federal benchmark published | 97.8% or better |
| Clean claim rate | Claims paid on first submission with no rework | No federal benchmark published | 97% or better |
| First-pass denial rate | Claims denied on first adjudication. For the Medicare comparison, take denied services count over submitted services count in the CY2025 PSPS file for the medical oncology and radiation oncology provider specialty codes. Suppressed cells make it a lower bound | CERT FY2025 Medicare fee-for-service improper payment rate 6.55%, claims July 2023 to June 2024 | 6% or lower |
| Cost to collect | Revenue cycle cost as a percentage of collections | No federal benchmark published | 3% to 6% of collections |
| Drug line first-pass denial rate | Part B drug lines denied on first adjudication, the oncology-specific metric | Same PSPS file, filtered to J-code HCPCS ranges | 4% or lower |
Typical values come from the named federal source in the table intro. Target values come from Luxen client data.
Prior authorization is not a front-office errand in oncology. It decides whether a drug the practice already bought is collectible.
Under CMS-0057-F, the prior authorization rule finalised in February 2024, impacted payers must return expedited decisions within 72 hours and standard decisions within 7 calendar days, beginning 1 January 2026. Impacted payers are Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care entities, and qualified health plan issuers on the Federally-Facilitated Exchanges. ERISA group plans are not covered. The same rule requires a specific reason for every denial and annual public reporting of authorization metrics, first posting due 31 March 2026. The Prior Authorization API is not required until 1 January 2027. That is a deadline you can hold a payer to on every pended chemotherapy request, and almost nobody tracks against it or cites it when a decision runs late.
For Medicare Advantage, 42 CFR 422.112(b)(8) states that approval of a prior authorization request for a course of treatment must be valid for as long as medically necessary to avoid disruptions in care, and requires a minimum 90-day transition period for an active course when a patient joins a new MA plan, during which the plan must not require reauthorization. Separately, 42 CFR 422.138(c) stops an MA plan denying an approved service later for lack of medical necessity. Very few practices cite any of this on appeal.
The failure is almost never a missing approval. It is an approval that no longer matches. A regimen changes at progression or for toxicity, the plan of care is updated in the EHR, and nothing pushes that change back to the authorization record. In the 2026 Luxen Oncology Revenue Cycle Audit, 9% of infusion claims carried an authorization that no longer matched the regimen billed. The fix is structural. Tie the authorization record to the active plan of care rather than a spreadsheet, and fire a re-verification on every regimen change. That is what our eligibility and prior authorization team runs.
In most specialties days in AR is an efficiency metric. In oncology it is a solvency metric, because the practice has already spent the money.
The practice buys the drug, pays the wholesaler on the wholesaler's terms, administers it, then waits for adjudication. Medicare pays most separately payable Part B drugs at 106 percent of ASP under 42 CFR 414.904, reduced by the 2 percent Medicare sequestration applied to the Medicare payment portion. A thin spread on a high acquisition cost cannot absorb a long AR cycle. Every 10 days removed from AR released a median $41,000 in cash for practices collecting $1.5M to $3M a year, and in oncology that funds the next drug order.
Part B drugs in single-dose containers require the JW modifier to report a discarded amount and JZ to attest there was none. JZ has been required since 1 July 2023, with CMS claims editing since 2 October 2023. Section 1847A(h) of the Social Security Act, implemented at 42 CFR 414.940, then runs a manufacturer refund on discarded amounts above an applicable percentage set at a baseline of 10 percent of total charges. The JW quantity is a federal data point: careless reporting is a compliance exposure, omitting it makes the claim unprocessable.
Hospitals and provider-based departments acquiring under 340B report modifier JG or TB depending on hospital type, mandatory for OPPS hospitals since 1 January 2023 and for non-OPPS entities since 1 January 2024. These are informational. 340B-acquired drugs are paid at the same ASP plus 6 percent as any other drug. Practices assuming the 340B discount changes the claim rate build the wrong expected payment and never see the underpayment.
Underpayments against contracted rates appeared on 7.8% of paid claims in our audit. On an office visit that is a rounding error. On a drug line it is the margin. Posting has to compare every paid line against contract automatically, because no human reads an oncology remittance line by line.
Radiation oncology sits inside the same practice and behaves like a different business. Almost no drug risk, and the revenue sits in planning, delivery and management units accruing against a fraction count.
Weekly radiation treatment management, CPT 77427, is reported once for every five fractions or treatment sessions, regardless of the actual time period in which the services are furnished. The Medicare Claims Processing Manual, Chapter 13, Section 70.1 states that a weekly unit of treatment management equals five fractions. Where three or four fractions remain at the end of a course, one unit may be billed; where one or two remain, it is not separately reported. Billing 77427 by calendar week under-bills every course with a machine down day or a missed session. In our review, weekly management units were billed short of documented fractions on 8% of radiation courses.
An IMRT course produces complex clinical treatment planning, 77263; an IMRT plan with dose-volume histograms, 77301; a 3D radiotherapy plan, 77295; guidance for localization of the target volume, 77387; CT guidance for placement of treatment fields, 77014; and delivery, 77385 simple or 77386 complex, or G6015 and G6016 where the payer requires them. Simulation codes are not separately payable on the same date as 77295. Each is a separate charge capture event, reconciled to the treatment record rather than the schedule.
Practices still budget for the Radiation Oncology Model. It has never started. Under CMS-5527-F2, published 29 August 2022, 42 CFR 512.205 provides that CMS will set the model performance period dates through future rulemaking, with at least six months of notice. No episode payment for radiation is in effect today. Our radiation oncology billing page carries the claim-level detail.
The 2026 Luxen Oncology Revenue Cycle Audit. Dataset: 8,900 oncology claims drawn from the Luxen claim audit of 61,400 claims, January 2025 to June 2026, with the oncology subset of 410 practice billing reviews over the same period. Counted: every infusion and radiation claim line against the treatment record, the authorization record and the contracted fee schedule.
The first four findings appear on no other page ranking for this subject.
Three-site medical oncology group, 7 physicians, seven months.
They arrived with days in AR at 58 and a first-pass denial rate of 15.8%, a third of denied dollars on drug lines. Authorizations lived in a shared spreadsheet, re-verified only when a scheduler noticed a regimen change. We tied the authorization record to the active plan of care, loaded drug and administration fee schedules for all four commercial payers, and moved AR to a highest-dollar-first queue. After seven months, days in AR were 34, the first-pass denial rate was 5.9%, and $412,000 in previously unworked drug and administration claims had been collected.
Chief Financial Officer, three-site medical oncology group
Luxen client data, 38 client practices, January 2024 to June 2026, and Luxen billing reviews, 410 practice billing reviews, January 2025 to June 2026.
A three-physician medical oncology practice collecting $4,000,000 a year at a 6% fee, carrying 50 days in AR and moving to the 33-day target above. This is arithmetic, not a promise. Check every line against your own figures.
Recurring annual gain: $198,000 plus $40,900 plus $59,400, or $298,300. One time: $90,200 plus $186,300. Substitute your own collections and denial rate before you believe any of it.
Want this arithmetic run on your own collections and denial rate?
Run my numbersOncology RCM runs 3 to 6 percent of collections. Nobody else on this subject publishes a number, so here is what moves ours.
Included at every level: eligibility and benefits verification, prior authorization, full-service medical billing, certified coding, scrubbing, posting with underpayment detection, denial root cause analysis, appeals, AR follow-up and monthly reporting by denial cause. No setup fee, no exit fee, month to month with 30 days notice. The in-house comparison below runs $299,400 a year, or 7.5% of collections, for the same practice.
The buy versus build case for a three-physician medical oncology practice collecting $4M a year. No competitor publishes this comparison. Run your own numbers against it.
| Line item | In-house | Luxen |
|---|---|---|
| Billing staff, fully loaded | 2.5 FTE at $62,000 average plus 28% burden, $198,400 | Included |
| Certified coder, oncology experienced | 0.5 FTE, $41,000 | Included |
| Authorization and benefits staff | 1.0 FTE, $52,800 loaded | Included |
| Clearinghouse and claim scrubbing | $7,200 | Included |
| Contract loading and underpayment detection | Usually not done | Included |
| Denial rework and appeals capacity | Absorbed by staff, unmeasured | Included |
| Coverage during turnover | 34% of practice managers replaced a biller in the past two years | Continuous |
| Total | $299,400, or 7.5% of collections | 3% to 6% of collections |
Keep it in-house when your billing team can already name its top three denial causes by dollar value. Outsource when it cannot, when one resignation would stop your claims, or when nobody owns denial follow-up. Practice managers estimated 11 staff hours a week on insurance calls and portal checks. Our medical billing companies directory compares options more broadly.
People search for which company is best. Wrong question: the answer depends on a fee schedule and a denial profile only you have.
Weight each criterion, score each candidate out of 5, and require evidence rather than assertion.
You have an incumbent. That is why most practices stay with a vendor they have already stopped trusting.
Signed BAA, read-only access to your existing practice management system, a parallel AR review while the incumbent finishes its runout, then a cutover date for new claims. We do not migrate data or ask you to change systems. Median time from signed BAA to first claims worked was 9 business days, and first recovered payments arrived a median of 17 days after work began. Plan for about two weeks to working claims and three to the first recovered payment.
Negotiate the runout before you sign anything new. Agree in writing who works claims with dates of service before the cutover, because unowned runout AR is where oncology practices lose six figures during a vendor change.
We work inside your existing system. No migration, no conversion, no new license. In the Luxen Practice Manager Survey 2026, 38% had changed EHR or practice management system in the past five years. Of those, 71% said collections dipped for at least six months after the switch. In oncology that dip lands on drug claims you have already paid for.
Automate in this order. First, eligibility and benefits verification per treatment date, high volume and fully rules-based. Second, expected payment per line against the loaded contract, the only way underpayment is detected. Third, authorization status tied to the plan of care. Fourth, denial routing by root cause rather than by date. Leave appeals and peer to peer to people. Patient communication sits alongside it, including the Medicare Prescription Payment Plan every Part D plan must now offer, which is what patient billing covers.
Credentialing and enrollment, registration and financial clearance, eligibility and benefits verification, prior authorization and pathway compliance, charge capture and coding, claim submission with payment posting and underpayment detection, then denials, appeals and AR follow-up. Each stage carries an oncology-specific failure mode, set out above. The most expensive is stage 4, where the authorization on file describes a regimen that has been superseded.
No ranking survives contact with your own numbers, because the right vendor depends on your payer mix, modality mix and denial profile. Score candidates instead on drug line competence, authorization architecture, denial reporting by root cause, contract and underpayment recovery, fee basis and exit terms, and whether they work inside your existing system. The scoring framework is above.
The 12-step version splits the same work more finely, separating pre-registration from registration, charge capture from coding, scrubbing from submission, posting from reconciliation, and denial management from appeals. Nothing is added. In oncology the split that matters is separating underpayment detection from posting, because 7.8% of paid claims in our audit came in below the contracted rate.
Luxen charges 3 to 6 percent of collections, month to month with 30 days notice, no setup fee and no exit fee. The rate moves on sites, whether you deliver radiation as well as medical oncology, trial volume, and the AR backlog on arrival. The in-house build for the same practice costs $299,400 a year, or 7.5% of collections.
Median time from signed BAA to first claims worked was 9 business days, and first recovered payments arrived a median of 17 days after work began. Across 38 client practices, net collection rate rose from 91.4% to 97.8% over the first six months. Backlogged AR older than 180 days takes longer and recovers at a lower rate.
Medical billing starts when there is a claim to build and ends when it is paid. Revenue cycle management starts before the patient is seen, with credentialing, eligibility and prior authorization, and continues past payment into underpayment detection. In oncology that distinction is financial, not semantic: the decisions making a drug claim collectible are all taken before the claim exists.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free revenue cycle assessment%20(1).avif)
